Robert W Lentz

9PUBLICATIONS
43CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer cell biologyInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 31, 2025
Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.

Robert W Lentz, Julie Lang, Todd M Pitts

|Jun 19, 2025
Oligometastatic pancreatic cancer: current state of management and emerging therapies.

Andrii Khomiak, Nicole B Balmaceda, Sumaya A Ghaffar

|Jul 24, 2024
Risk Without Reward: Differing Patterns of Chemotherapy Use Do Not Improve Outcomes in Stage II Early-Onset Colon Cancer.

Jacob B Leary, Junxiao Hu, Alexis Leal

|Jun 13, 2024
A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer.

Robert W Lentz, Tyler J Friedrich, Patrick J Blatchford

|Sep 29, 2023
Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment.

Jesus Amo-Aparicio, Adrian Dominguez, Shaikh M Atif

|Sep 20, 2021
Transarterial Radioembolization in Patients With Unresectable Colorectal Cancer Liver Metastases.

Robert W Lentz, Wells A Messersmith

Pageof 2

Frequent Collaborators

4 joint publications

Wells A Messersmith

4 joint publications

Christopher H Lieu

3 joint publications

Todd M Pitts

3 joint publications

Sunnie S Kim